Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study

Dr. John F. Seymour presents preliminary results from the Phase 1 CaDAnCe-101 study, highlighting the efficacy and safety of the BTK degrader BGB-16673 in relapsed or refractory Waldenström macroglobulinemia, demonstrating high response rates, rapid improvements in cytopenias, and promising activity across diverse mutation profiles.

John Fox, MD, MHA, Spectrum Health

John G. Gosney, MD, FRCPath, Royal Liverpool

John Glaser, PhD

Latest:

HITECH Lays the Foundation for More Ambitious Outcomes-Based Reimbursement

The US healthcare system has decades of research and anecdotal evidence suggesting the potential transformational power of healthcare information technology (HIT).

John Gordan, MD, PhD

Latest:

Dr. Gordan on Molecular Diagnostics in Biliary Tract Cancers

John Gordan, MD, PhD, assistant professor, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how the adoption of molecular diagnostics has helped further treatment efforts in biliary tract cancers.

John Gribben, MD, DSc, Barts Cancer Institute

John H. Sampson, MD, PhD, MBA, MHSc

Latest:

Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

John H. Stewart, IV, MD

Latest:

Multidisciplinary Melanoma Program Facilitates Patient Care and Clinical Research

The Malignant Melanoma Program at Wake Forest Baptist Health employs a multidisciplinary approach for the management of patients with all stages of this disease. The goals of the program are centered on unequivocal excellence in all areas of care for patients with malignant melanoma.

John H. Suh, MD

Latest:

The Jury's Still Out on Whole-Brain Radiation Therapy for Brain Metastases

Despite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.

John H. Ward, MD

Latest:

Dr. Ward on Multigene Testing in Breast Cancer

John H. Ward, MD, discusses his preferences in multilane testing for patients with hormone receptor–positive, node-negative breast cancer.

John Haanen, MD, PhD

Latest:

Dr. John Haanen on the Role of PD-L1 in Lung Cancer

John Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.